Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: A study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG)
Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: A study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG)
复制标题
DOI：
10.1016/j.ejca.2006.03.029
复制
发表时间：
2006-09-01
影响因子：
8.4
通讯作者：
Blay, Jean-Yves
中科院分区：
文献类型：
--
作者：
Van Glabbeke, Martine;Verweij, Jaap;Blay, Jean-Yves
本研究的目的是确定伊马替尼治疗毒性的预后因素。该研究基于 942 名胃肠道间质瘤 (GIST) 患者，随机接受不同剂量的伊马替尼治疗。研究了通用毒性标准 (CTC) 2 级或以上（非血液学）或 3 级或 4 级（血液学）发生的毒性与伊马替尼剂量、年龄、性别、体能状态、原发疾病部位、试验开始时病变部位和大小、基线血液学和生物学参数之间的相关性。贫血与剂量和基线血红蛋白水平相关，中性粒细胞减少与基线中性粒细胞计数和血红蛋白水平相关。非血液学毒性的风险呈剂量依赖性，女性患者（水肿、恶心、腹泻）、高龄患者（水肿、皮疹、疲劳）、体力状态不佳（疲劳和恶心）、既往化疗（疲劳）、已确定胃肠道来源的肿瘤（腹泻）和小病变（皮疹）患者的非血液毒性风险较高。提出了一种可在临床上针对个体患者使用的多变量风险计算器。 (c) 2006 年，爱思唯尔有限公司出版。
The aim of this study was to identify prognostic factors for toxicity to treatment with imatinib. The study was based on 942 patients with gastrointestinal stromal tumours (GIST) randomised to receive imatinib at different doses. The correlation between toxicities occurring with a Common Toxicity Criteria (CTC) grade 2 or more (non-haematological) or grade 3 or 4 (haematological) and imatinib dose, age, sex, performance status, original disease site, site and size of lesions at trial entry, baseline haematological and biological parameters was investigated. Anaemia was correlated with dose and baseline haemoglobin level, and neutropaenia with baseline neutrophil count and haemoglobin level. The risk of non-haematological toxicities was dose dependent and higher in females (oedema, nausea, diarrhoea), and in patients of advanced age (oedema, rash fatigue), poor performance status (fatigue and nausea), prior chemotherapy (fatigue), tumour of identified gastrointestinal origin (diarrhoea) and small lesions (rash). A multivariate risk calculator that can be used in the clinic for individual patients is proposed. (c) 2006 Published by Elsevier Ltd.